Vascular smooth muscle dysfunction induced by monomethylarsonous acid (MMAIII): A contributing factor to arsenic-associated cardiovascular diseases

Environmental Research

Volumn 108, Issue 3, 2008, Pages 300-308

  Bae, Ok Nam ^a   Lim, Eun Kyung ^a   Lim, Kyung Min ^a,b   Noh, Ji Yoon ^a   Chung, Seung Min ^a   Lee, Moo Yeol ^c   Yun, Yeo Pyo ^d   Kwon, Seong Chun ^e   Lee, Jun Ho ^f   Nah, Seung Yeol ^f   Chung, Jin Ho ^a  

^a Seoul National University   (South Korea)

^b AmorePacific Corporation   (South Korea)

^c Chonnam National University   (South Korea)

^d Chungbuk National University   (South Korea)

^e Catholic Kwandong University   (South Korea)

^f Konkuk University   (South Korea)

Author keywords

Arsenic; Cardiovascular diseases; Monomethylarsonous acid (MMAIII); Smooth muscle dysfunction; Vasoconstriction

Indexed keywords

CALCIUM CHANNEL L TYPE; CALCIUM ION; ENDOTHELIN 1; MONOMETHYLARSONOUS ACID; ORGANOARSENIC DERIVATIVE; PHENYLEPHRINE; SEROTONIN; UNCLASSIFIED DRUG;

ARSENIC; CARDIOVASCULAR DISEASE; DRINKING WATER; HEALTH IMPACT; INHIBITION; INORGANIC ACID; METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ISOLATED ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE CONTRACTION; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION;

ANIMALS; ARSENIC; CALCIUM; CALCIUM CHANNELS, L-TYPE; CARDIOVASCULAR DISEASES; L-LACTATE DEHYDROGENASE; MALE; MUSCLE, SMOOTH, VASCULAR; ORGANOMETALLIC COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; VASOCONSTRICTION;

RATTUS;

EID: 54049146246     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2008.06.012     Document Type: Article

References (55)

1. Abernathy C.O., Thomas D.J., and Calderon R.L. Health effects and risk assessment of arsenic. J. Nutr. 133 (2003) 1536S-1538S
2. 2+-dependent regulation of vascular tone. J. Anesth. 21 (2007) 220-231
3. Aposhian H.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., Yip L., Zakharyan R.A., Maiorino R.M., Dart R.C., Tircus M.G., Gonzalez-Ramirez D., Morgan D.L., Avram D., and Aposhian M.M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13 (2000) 693-697
4. Benoit J.N., and Taylor M.S. Vascular reactivity following ischemia/reperfusion. Front. Biosci. 2 (1997) e28-e33
5. 2+ influx into vascular smooth muscle. J. Cardiovasc. Pharmacol. 43 (2004) 504-513
6. Cohn J.N. Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am. J. Hypertension 14 (2001) 258S-263S
7. Davignon J., and Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109 (2004) III27-III32
8. Deanfield J.E., Halcox J.P., and Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 115 (2007) 1285-1295
9. Del Razo L.M., Styblo M., Cullen W.R., and Thomas D.J. Determination of trivalent methylated arsenicals in biological matrices. Toxicol. Appl. Pharmacol. 174 (2001) 282-293
10. Eblin K.E., Bowen M.E., Cromey D.W., Bredfeldt T.G., Mash E.A., Lau S.S., and Gandolfi A.J. Arsenite and monomethylarsonous acid generate oxidative stress response in human bladder cell culture. Toxicol. Appl. Pharmacol. 217 (2006) 7-14
11. Engel R.R., and Smith A.H. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch. Environ. Health 49 (1994) 418-427
12. Fortuno A., Muniz P., Ravassa S., Rodriguez J.A., Fortuno M.A., Zalba G., and Diez J. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 34 (1999) 138-143
13. Gregus Z., Gyurasics A., and Csanaky I. Biliary and urinary excretion of inorganic arsenic: monomethylarsonous acid as a major biliary metabolite in rats. Toxicol. Sci. 56 (2000) 18-25
14. Gutstein W.H., and Perez C.A. Contribution of vasoconstriction to the origin of atherosclerosis: a conceptual study. Trends. Cardiovasc. Med. 14 (2004) 257-261
15. 2+ oscillations in canine pulmonary artery smooth muscle cells. Circ. Res. 81 (1997) 812-823
16. Harris L.M., Faggioli G.L., Shah R., Koerner N., Lillis L., Dandona P., Izzo J.L., Snyder B., and Ricotta J.J. Vascular reactivity in patients with peripheral vascular disease. Am. J. Cardiol. 76 (1995) 207-212
17. Horowitz A., Menice C.B., Laporte R., and Morgan K.G. Mechanisms of smooth muscle contraction. Physiol. Rev. 76 (1996) 967-1003
18. Hughes M.F. Biomarkers of exposure: a case study with inorganic arsenic. Environ. Health Perspect. 114 (2006) 1790-1796
19. Kerns W., Schwartz L., Blanchard K., Burchiel S., Essayan D., Fung E., Johnson R., Lawton M., Louden C., MacGregor J., Miller F., Nagarkatti P., Robertson D., Snyder P., Thomas H., Wagner B., Ward A., and Zhang J. Drug-induced vascular injury-a quest for biomarkers. Toxicol. Appl. Pharmacol. 203 (2005) 62-87
20. Kitazawa T., Polzin A.N., and Eto M. CPI-17-deficient smooth muscle of chicken. J. Physiol. 557 Pt 2 (2004) 515-528
21. Kruger K., Gruner J., Madeja M., Hartmann L.M., Hirner A.V., Binding N., and Musshoff U. Blockade and enhancement of glutamate receptor responses in Xenopus oocytes by methylated arsenicals. Arch. Toxicol. 80 (2006) 492-501
22. Landry D.W., and Oliver J.A. The pathogenesis of vasodilatory shock. N. Engl. J. Med. 345 (2001) 588-595
23. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., and Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 72 (2000) 5172-5177
24. Lee J.L., Bae O.N., Chung S.M., Lee M.Y., and Chung J.H. Menadione induces endothelial dysfunction mediated by oxidative stress and arylation. Chem. Biol. Interact. 137 (2001) 169-183
25. Lee M.Y., Jung B.I., Chung S.M., Bae O.N., Lee J.Y., Park J.D., Yang J.S., Lee H., and Chung J.H. Arsenic-induced dysfunction in relaxation of blood vessels. Environ. Health Perspect. 111 (2003) 513-517
26. + current inhibition. Mol. Pharmacol. 68 (2005) 1114-1126
27. Lee M.Y., Lee Y.H., Lim K.M., Chung S.M., Bae O.N., Kim H., Lee C.R., Park J.D., and Chung J.H. Inorganic arsenite potentiates vasoconstriction through calcium sensitization in vascular smooth muscle. Environ. Health Perspect. 113 (2005) 1330-1335
28. Lee C.H., Chang H.R., Chen J.S., Chen G.S., and Yu H.S. Defective adrenergic responses in patients with arsenic-induced peripheral vascular disease. Angiology 58 (2007) 161-168
29. Lin S., Del Razo L.M., Styblo M., Wang C., Cullen W.R., and Thomas D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol. 14 (2001) 305-311
30. Lynn S., Gurr J.R., Lai H.T., and Jan K.Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 86 (2000) 514-519
31. Martin H.B., McCallum M., Stofer W.D., and Eichinger M.R. Kavain attenuates vascular contractility through inhibition of calcium channels. Planta Med. 68 (2002) 784-789
32. Mead M.N. Arsenic: in search of an antidote to a global poison. Environ. Health Perspect. 113 (2005) A378-A386
33. Morano I. Tuning smooth muscle contraction by molecular motors. J. Mol. Med. 81 (2003) 481-487
34. Navas-Acien A., Sharrett A.R., Silbergeld E.K., Schwartz B.S., Nachman K.E., Burke T.A., and Guallar E. Arsenic exposure and cardiovascular disease: a systematic review of the epidemiologic evidence. Am. J. Epidemiol. 162 (2005) 1037-1049
35. Nesnow S., Roop B.C., Lambert G., Kadiiska M., Mason R.P., Cullen W.R., and Mass M.J. DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem. Res. Toxicol. 15 (2002) 1627-1634
36. Orallo F. Regulation of cytosolic calcium levels in vascular smooth muscle. Pharmacol. Ther. 69 (1996) 153-171
37. 2+, and tension in intact smooth muscles. Am. J. Physiol. 260 (1991) C917-C925
38. Parekh A.B., and Putney Jr. J.W. Store-operated calcium channels. Physiol. Rev. 85 (2005) 757-810
39. Partridge C.R., Williams E.S., Barhoumi R., Tadesse M.G., Johnson C.D., Lu K.P., Meininger G.A., Wilson E., and Ramos K.S. Novel genomic targets in oxidant-induced vascular injury. J. Mol. Cell. Cardiol. 38 (2005) 983-996
40. Pastor C.M. Hyperthermia decreases the response to vasoconstrictors in rat portal veins. Eur. J. Pharmacol. 494 (2004) 191-197
41. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., and Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163 (2000) 203-207
42. Sanders K.M. Invited review: mechanisms of calcium handling in smooth muscles. J. Appl. Physiol. 91 (2001) 1438-1449
43. Schiffrin E.L. Vascular stiffening and arterial compliance. Implications for systolic blood pressure. Am. J. Hypertension 17 (2004) 39S-48S
44. Shan J.J., Li B., Taniguchi N., and Pang P.K. Inhibition of membrane L-type calcium channel activity and intracellular calcium concentration by 24R, 25-dihydroxyvitamin D3 in vascular smooth muscle. Steroids 61 (1996) 657-663
45. Smith K.R., Klei L.R., and Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 280 (2001) L442-L449
46. Smulyan H., and Safar M.E. Systolic blood pressure revisited. J. Am. Coll. Cardiol. 29 (1997) 1407-1413
47. Styblo M., Del Razo L.M., Vega L., Germolec D.R., LeCluyse E.L., Hamilton G.A., Reed W., Wang C., Cullen W.R., and Thomas D.J. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 74 (2000) 289-299
48. Styblo M., Drobna Z., Jaspers I., Lin S., and Thomas D.J. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ. Health Perspect. 110 Suppl. 5 (2002) 767-771
49. 2+ level and contraction on exposure of rat aorta to lysophosphatidylcholine. Eur. J. Pharmacol. 378 (1999) 177-186
50. Taggart M.J., and Wray S. Hypoxia and smooth muscle function: key regulatory events during metabolic stress. J. Physiol. 509 Pt 2 (1998) 315-325
51. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. Beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
52. Tsai S.H., Liang Y.C., Chen L., Ho F.M., Hsieh M.S., and Lin J.K. Arsenite stimulates cyclooxygenase-2 expression through activating IkappaB kinase and nuclear factor kappaB in primary and ECV304 endothelial cells. J. Cell. Biochem. 84 (2002) 750-758
53. Tseng C.H. Blackfoot disease and arsenic: a never-ending story. J. Environ. Sci. Health C Environ. Carcinogenesis Ecotoxicol. Rev. 23 (2005) 55-74
54. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 181-182 (2002) 211-217
55. Yoshida T., Yamauchi H., and Fan Sun G. Chronic health effects in people exposed to arsenic via the drinking water: dose-response relationships in review. Toxicol. Appl. Pharmacol. 198 (2004) 243-252